Product image of Linagliptin/Metformin Sandoz (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Metformin Sandoz

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Metformin Sandoz (Metformin Hydrochloride, Linagliptin)

Linagliptin/Metformin, the active ingredient in Linagliptin/Metformin Sandoz, is a DPP‑4 inhibitor; biguanide combination presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise in adult patients, working by enhancing insulin secretion while decreasing hepatic glucose output.

GNH India supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Sandoz S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin is used in the treatment of type 2 diabetes, a chronic metabolic disorder requiring glycemic control.

  • Type 2 diabetes mellitus: improves overall glycemic control when added to diet, exercise and existing therapy.
  • Patients inadequately controlled on metformin alone: provides additional DPP‑4 inhibition to lower HbA1c.
  • Adults requiring combination therapy: reduces pill burden by delivering two antidiabetic agents in a single tablet.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4, preventing the breakdown of incretin hormones (GLP‑1 and GIP) and thereby enhancing glucose‑dependent insulin secretion while suppressing glucagon release. Metformin primarily decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity. These mechanisms act synergistically to achieve durable glycemic reduction without causing hypoglycemia when used alone.

Side Effects

Linagliptin/Metformin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Nausea: mild stomach upset often transient.
  • Diarrhea: loose stools, usually self‑limiting.
  • Abdominal discomfort: cramps or pain in the abdomen.
  • Headache: mild to moderate intensity.
  • Dizziness: sensation of light‑headedness.
  • Metallic taste: altered taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic condition.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Hepatic failure: signs of liver dysfunction.
  • Anaphylactic reaction: severe allergic response requiring emergency care.

Precautions & Warnings

Before prescribing Linagliptin/Metformin, clinicians should consider several safety precautions to minimize risk.

  • Renal function assessment: evaluate creatinine clearance before initiation and periodically.
  • Hepatic impairment monitoring: avoid use in patients with severe liver disease.
  • Lactic acidosis risk: contraindicated in conditions predisposing to hypoxia or severe infection.
  • Elderly patients: start at lower dose and monitor for tolerance.
  • Concomitant heart failure: use with caution in patients with NYHA class III/IV.
  • Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Avoid Interactions

Linagliptin/Metformin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycemia.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin levels.
  • Iodinated contrast agents: may precipitate metformin‑associated renal dysfunction.
  • Rifampicin: reduces linagliptin exposure, diminishing glucose control.
  • Cimetidine: can increase metformin concentrations.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and potassium.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • NSAIDs: can impair renal function, increasing metformin accumulation.
  • Alcohol: enhances risk of lactic acidosis.

Frequently Asked Questions

Linagliptin/Metformin Sandoz is prescribed as an adjunct to diet and exercise for adults with type 2 diabetes mellitus. It combines a DPP‑4 inhibitor and a biguanide to improve overall glycemic control when monotherapy is insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, it enhances glucose‑dependent insulin secretion and reduces glucagon release, helping lower blood glucose levels.

The specific dose of Linagliptin/Metformin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Only a qualified prescriber should set the dosage regimen.

Safety data for Linagliptin/Metformin in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with separate tablets of metformin and a DPP‑4 inhibitor, the fixed‑dose combination reduces pill burden and may improve adherence. Unlike sulfonylureas, it carries a lower risk of hypoglycemia, and unlike some newer agents, it does not require dose adjustment in mild to moderate renal impairment.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks include lactic acidosis, especially in patients with renal or hepatic impairment, severe hypoglycemia when combined with insulin or sulfonylureas, acute pancreatitis, and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these occur.

The combination should be avoided in patients with severe renal impairment, severe hepatic disease, a history of lactic acidosis, or known hypersensitivity to either component. It is also contraindicated in individuals with certain cardiac conditions that predispose to hypoxia.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT